Related Experiment Video
Updated: Sep 20, 2026
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
Messenger RNA expression profiling of genes involved in epidermal growth factor receptor signalling in human cancer
Amelia K Petch1, Muhammad Sohail, Marcus D Hughes
1Pharmaceutical Sciences Research Institute, Aston University, Aston Triangle, Birmingham B4 7ET, UK.
Abstract:
Scanning oligodeoxynucleotide (ODN) arrays appear promising in vitro tools for the prediction of effective antisense reagents but their usefulness has not yet been reported in mammalian systems. In this study, we have evaluated the use of scanning ODN arrays to predict efficacious antisense ODNs targeting the human epidermal growth factor receptor (EGFR) mRNA in a human epidermoid cancer cell line and in primary human glioma cells. Hybridisation accessibility profile of the first 120nt in the coding region of the human EGFR mRNA was determined by hybridising a radiolabelled EGFR transcript to a scanning array of 2684 antisense sequences ranging from monomers to 27-mers. Two ODNs, AS1 and AS2, complementary to accessible sequences within the EGFR mRNA, were designed and their ability to hybridise to EGFR mRNA was further confirmed by in vitro RNase H-mediated cleavage assays. Phosphorothioate-modified 21-mer AS1 and AS2 ODNs inhibited the growth of an established human A431 cancer cell line as well as primary glioma cells from human subjects when delivered as cationic lipoplexes. In contrast, scrambled controls and AS3-an antisense ODN complementary to an inaccessible site in EGFR mRNA-were inactive. Western blots showed that AS1 ODN exhibited a dose-dependent inhibition of EGFR protein expression in A431 cells in the nanomolar range. Microarray-based gene expression profiling studies of A431 cells treated with the 21-mer phosphorothioate AS1 ODN demonstrated successful inhibition of downstream signalling molecules further confirming the effective inhibition of EGFR expression in human cancer cells by antisense ODNs designed by scanning ODN array technology.
Insights
Scanning oligodeoxynucleotide (ODN) arrays effectively predict antisense ODNs targeting human epidermal growth factor receptor (EGFR) mRNA in cancer cells. This technology shows promise for developing novel cancer therapies.
Area of Science:
- Molecular Biology
- Cancer Research
- Oligonucleotide Therapeutics
Background:
- Antisense oligodeoxynucleotides (ODNs) are promising for targeted gene silencing.
- Predicting effective antisense ODNs in mammalian systems remains challenging.
- Scanning ODN arrays offer a potential in vitro method for identifying efficacious antisense sequences.
Purpose of the Study:
- To evaluate scanning ODN arrays for predicting effective antisense ODNs against human epidermal growth factor receptor (EGFR) mRNA.
- To assess the efficacy of designed antisense ODNs in human cancer cell lines and primary glioma cells.
Main Methods:
- Utilized scanning ODN arrays to determine the hybridization accessibility profile of human EGFR mRNA.
- Designed and synthesized antisense ODNs (AS1, AS2) complementary to accessible EGFR mRNA sites.
- Validated ODN efficacy using in vitro RNase H-mediated cleavage assays, cell growth inhibition studies, Western blots, and gene expression profiling.
Main Results:
- Scanning ODN arrays successfully identified accessible sites on EGFR mRNA for antisense targeting.
- Phosphorothioate-modified AS1 and AS2 ODNs significantly inhibited cancer cell growth and EGFR protein expression in a dose-dependent manner.
- Scrambled controls and ODNs targeting inaccessible sites showed no inhibitory effect.
- Gene expression profiling confirmed effective inhibition of EGFR downstream signaling.
Conclusions:
- Scanning ODN array technology is a valuable tool for predicting efficacious antisense ODNs in mammalian systems.
- Antisense ODNs designed via this method can effectively inhibit EGFR expression and downstream signaling in human cancer cells.
- This approach holds significant potential for the development of novel antisense-based cancer therapeutics.
